These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15855721)

  • 1. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.
    Taguchi M; Hongou K; Yagi S; Miyawaki T; Takizawa M; Aiba T; Hashimoto Y
    Drug Metab Pharmacokinet; 2005 Apr; 20(2):107-12. PubMed ID: 15855721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
    Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
    Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
    Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication.
    Ninomiya H; Mamiya K; Matsuo S; Ieiri I; Higuchi S; Tashiro N
    Ther Drug Monit; 2000 Apr; 22(2):230-2. PubMed ID: 10774639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
    Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition.
    Simon C; Stieger B; Kullak-Ublick GA; Fried M; Mueller S; Fritschy JM; Wieser HG; Pauli-Magnus C
    Acta Neurol Scand; 2007 Apr; 115(4):232-42. PubMed ID: 17376120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.
    Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E
    Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
    Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
    Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
    Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
    Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Phenytoin Based on NONMEM in Patients with Intracranial Tumor During the First Week of Post-Craniotomy.
    Li ZD; Liu M; Li L; Wan JH; Lei Z; Huang YA
    Curr Drug Metab; 2016; 17(7):721-8. PubMed ID: 27174459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenytoin-diazepam interaction.
    Murphy A; Wilbur K
    Ann Pharmacother; 2003 May; 37(5):659-63. PubMed ID: 12708941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study.
    Ebid AH; Ahmed MM; Mohammed SA
    Ther Drug Monit; 2007 Jun; 29(3):305-12. PubMed ID: 17529887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.